Prochlorperazine

Form	12.5mg/mL prochlorperazine mesilate solution for injection	Store below 25°C in original packaging to protect from light
Reconstitution	Already in solution • Use gloves when opening ampoules • Draw up using a 5 micron filter needle	
Compatibility & Stability	N/A	
Administration	**IM Injection** Give by deep intramuscular injection **IV Injection (Unlicensed in management of acute migraine)** • Dilute 1ml to 5ml with Sodium chloride 0.9% to aid slow administration • Give slowly at a maximum rate of 6.25mg/minute. Do not give more than 12.5mg as a single dose* • The patient must lie down during and for 30 minutes after administration to reduce the risk of hypotension.	
Monitoring	Monitor blood pressure and heart rate for at least 30 minutes post-injection Monitor ECG particularly if cardiovascular risk factors or if the patient is being admitted as an inpatient.	
Acute reactions	Monitor closely patients with epilepsy or a history of seizures, as prochlorperazine may lower the seizure threshold Monitor ECG particularly if cardiovascular risk factors or if the patient is being admitted as an inpatient. Also see below • postural hypotension, syncope and dizziness. • vasospasm, tachycardia, increased pulse rate • hypersensitivity, including anaphylaxis, angioedema, urticaria • extrapyramidal reactions • injection site reactions. Contains sulfites: may cause hypersensitivity reactions and bronchospasm.	
Antidote	Ensure suitable antidote, e.g. benztropine, is readily available in the event of a dystonic reaction	
Additional Information	Stemetil should be avoided in patients with hepatic or renal dysfunction, Parkinson's disease, hypothyroidism, cardiac failure, phaeochromocytoma, myasthenia gravis, and prostate hypertrophy. It should be avoided in patients with a history of narrow angle glaucoma or agranulocytosis. *12.5mg prochlorperazine mesilate is equivalent to approx. 8.3mg prochlorperazine base. US licensed product containing a different salt (prochlorperazine edisylate) is licensed for IV administration at dose of 10mg prochlorperazine base. Dose of 12.5 mg prochlorperazie mesilate is closest reasonable dose.	

Information provided relates to Stemetil® (Sanofi) last updated 27/8/26

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542